Two new investors lead funding round as company looks to accelerate commercial rollout in key US market as well as Europe and Australia
Mainstay Medical has raised $125 million in its biggest equity fundraising to date as it looks to accelerate the company’s expansion across US, European and Australian markets. The Dublin-based group’s ReActiv8 is designed to treat chronic lower back pain by electrically stimulating nerves in muscles supporting the lower spine.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Mainstay Medical Reactiv8 Chronic Lower Back Pain Funding Expansion Investors